Panel nixes Merck challenge to Sanofi's Nasacort ad claims; Wales MS patients win access to Bayer drug;

> A national panel has nixed a Merck ($MRK) challenge to advertising claims by Sanofi's ($SNY) Chattem over the company's newly launched Nasacort allergy nasal spray. Story

> Multiple sclerosis patients in Wales have won access to Bayer's Sativex. Report

> Basilea Pharmaceutica has appointed David Veitch as its chief commercial officer. Release

> The FDA is seeking a new director for the Center for Drug Evaluation and Research's Office of Medical Policy, which oversees the Office of Prescription Drug Promotion. More

> A judge has side with Depomed in its patent litigation suit against Actavis ($ACT), whose generic of Depomed's Gralise will now be delayed until 2024. Release

> India's Organization of Pharmaceutical Producers of India is asking the Department of Pharmaceuticals to make its Uniform Code of Pharmaceutical Marketing Practices a statutory code. More

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.